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Argentina, Belgium (French and Flemish), France, Romania, Czech Republic, Slovakia, 
Poland and Russia. METHODS: The adaptation in each country required 3 stages: 
Translation, cognitive debrieﬁng and a validation survey. The translation process 
adopted the dual panel (bilingual followed by lay panel) methodology to ensure the 
‘naturalness’ of language. Cognitive-debrieﬁng interviews assessed face and content 
validity with local RA patients. The validation survey tested the psychometric proper-
ties of the new scales and included the Nottingham Health Proﬁle (NHP) as a com-
parator. RESULTS: The sample size for France was inadequate to test its psychometric 
properties. Mean scores on the new versions of the RAQoL ranged from 10.7 to 15.7 
(maximum possible  30). Internal consistency ranged from 0.90–0.97 and test-retest 
reliability from 0.85–0.99 with 7 countries above 0.90. Scores were related to self-
perceived severity in all countries, reaching signiﬁcance in 7 out of 10 countries and 
were signiﬁcantly related to self-perceived general health in all countries. Mean cor-
relations with NHP sections were highest (as expected) with energy level, pain and 
physical mobility (average correlations 0.71–0.74) and lowest with emotional reac-
tions, sleep disturbance and social isolation (average correlations 0.50–0.67). CON-
CLUSIONS: The present study indicates that (with the exception of France which 
requires additional validation data) the new language versions of the RAQoL meet 
the standards of the original UK version and the other 8 existing versions. The new 
instruments represent valid and reliable tools for measuring QoL in international 
clinical trials in RA.
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HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH PSORIATIC 
ARTHRITIS
Daudén E1, Moreno JC2, Gomez-Reino J3, Rodriguez-Valverde V4, Gratacos J5, Sabater FJ6, 
Casado MA7
1Hospital La Princesa, Madrid, Spain, 2Hospital Reina Sofía, Córdoba, Andalucía, Spain, 
3Complexo Hospitalario Universitario, Santiago de Compostela, Galicia, Spain, 4Hospital 
Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, 5Hospital Parc Taulí, 
Sabadell, Cataluña, Spain, 6Schering-Plough S.A, Alcobendas, Spain, 7Pharmacoeconomics & 
Outcomes Research Iberia, Madrid, Spain
OBJECTIVES: To assess the impact of psoriatic arthritis on the quality of life of 
patients due to the illness. METHODS: An observational study was designed recruit-
ing 287 patients from 18 Spanish centers to assess psoriatic arthritis patients’ quality 
of life. Data about the demographic characteristics of the sample were collected. 
Measures of the severity of the psoriatic arthritis were: 1) Psoriasis Area and Severity 
Illness (PASI scores 0–72, from low to high severity of psoriasis); 2) Number of painful 
or inﬂamed joints; 3) Health Assessment Questionnaire (HAQ; assessment of illness 
impact in different types of activities). Assessment of health-related quality of life 
(HRQL) was performed using: 1) Quality of life questionnaire EuroQol-5D (EQ-5D 
scores 0–3; higher scores are related to worse HRQL) and its Visual Analogue Scale 
(VAS scores 0–100; higher scores represent a best HQRL); and 2) Quality of life 
questionnaire Short Form-36 (SF-36 scores 0–100; higher scores are related to best 
HRQL). Frequency distribution, means and SD of the data were shown. RESULTS: 
The majority of cases were males (55.7%) and the mean age was 52.40 o 12.53 years. 
Mean number of inﬂamed joints was 2.62 o 4.06 and mean number of painful joints 
was 4.97 o 6.85. Mean value of PASI scores was 3.73 o 5.83. Biologic drugs were 
used in 25% of the patients. Mean values in the domains of EQ-5D with a worst 
self-assessment were: pain, 1.86 o 0.56 and usual activities, 1.52 o 0.55. Mean score 
of VAS was 60.41 o 20.08. Domains in SF-36 where the patients report a worst 
functioning were: physic role, 50.76 o 43.43, body pain, 49.35 o 25.69, general health, 
43.78 o 19.75, vitality 50.01 o 22.58 and physical summary component, 37.88 o 
10.87. This tendency is related to the results shown in HAQ questionnaire where more 
than 40% of patients have some difﬁculties in daily/usual activities. CONCLUSIONS: 
Psoriatic arthritis is associated with an impairment of HRQL that is mainly character-
ized by body pain and a worst functioning in daily activities.
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IS BODY-MASS-INDEX A PREDICTIVE FACTOR FOR CLINICAL 
OUTCOME IN PATIENTS WITH MONOSEGMENTAL LUMBAR FUSION?
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OBJECTIVES: Obesity is often considered as a risk-factor for higher complication rates 
and worse clinical outcome of fusion surgery in the lumbar spine and is therefore 
sometimes not performed in obese patients despite relative indication for surgery. The 
goal of this study was to evaluate whether BMI is a predictive factor for clinical 
outcome after monosegmental fusion surgery in the lumbar spine. METHODS: The 
present study is a retrospective analysis of prospectively collected data in a consecutive 
series of patients. Between April 2002 and April 2007, a total of 467 patients under-
went monosegmental lumbar fusion in a single spine center. Preoperatively, at 6 weeks 
and at 1 year follow-up, SF36 and Oswestry-Disability-Index scores were collected. 
We excluded patients who underwent surgery due to infections, tumor and trauma, as 
well as revision surgeries, and all patients with incomplete datasets, so that 223 patients 
were included in the study. Of those patients, variables considered as risk-factors like 
age, BMI and the presence of comorbidities like diabetes mellitus were assessed from 
the medical records. A multiple regression model for those parameters and clinical 
outcome was cretated. RESULTS: In an unadjusted model, BMI did not at all predict 
clinical outcome, in a multivariate model adjusted for baseline outcome values of SF36, 
Oswestry-Disability index and age, a slight trend towards negative correlation between 
BMI and outcome could be shown (p  0.06) at one-year follow-up. CONCLUSIONS: 
This study suggests that BMI alone is not a good predictor of clinical outcome of 
monosegmental lumbar fusion one year after surgery and that therefore this kind 
of surgery should not be withheld from patients only because of obesity.
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OBJECTIVES: The aim was to study differences in baseline scores of two health 
related quality of life (HRQOL) hip/knee osteoarthritis questionnaires, between dif-
ferent anxiety levels. METHODS: We applied questionnaires in a sample before 
intervention. The questionnaires were OAKHQOL, score from 0 (the worst) to 100 
(the best); WOMAC with a range from 0 (the best) to 100 (the worst); and one item 
about anxiety which grouped patients into 5 levels. We categorized into 3 groups: 
“nothing/a little anxious”, “moderately anxious” and “very/extremely anxious”. We 
analyzed differences through analysis of variance with Scheffé’s test. RESULTS: 729 
patients were included. The anxiety groups were: 411 “noting/a little anxious”, 218 
“moderately anxious” and 100 “very/extremely anxious”. We found worse scores as 
anxiety level increase and statistically signiﬁcant differences (p  0.001) in nearly all 
OAKHQOL dimensions. In physical activity, mean (DS) of 31.44 (20.87) in the lowest 
group, 22.91(15.19) in “moderately”, and 14.56(13.34) in “very/extremely” group; 
in pain we observed 36.53(25.45) in “noting/little”, 24.96(19.61) in “moderately”, 
and 17.23(16.91) in “very/extremely” group; in mental health, 61.39(20.63) in the 
lowest group, 41.30(18.38) in moderate, and 24.75(13.05) in the highest group; and 
in social activities we observed differences (p  0.002) between the lowest (mean 59.07 
(26.84)) and the highest anxiety groups, (49.59 (26.05)). Social support didn’t show 
any relation. In WOMAC there were differences (p  0.001) amongst the three anxiety 
groups. In pain, the baseline score was 47.73 (19.24) in “nothing/little group, 55.23 
(16.77) in “moderately” and 63.99 (18.38) in “very/extremely anxious”; in stiffness, 
were 47.04 (24.29) in the lowest group, 53.88 (21.70) in moderate and 61.25 (26.32) 
in the highest anxiety group; ﬁnally, the baseline data in functionality were 52.58 
(20.36) in the lowest group, 60.29 (16.98) in moderate, and 69.44 (18.56) in the 
highest anxiety group. CONCLUSIONS: These ﬁndings show an association between 
anxiety levels and HRQOL baseline scores.
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OBJECTIVES: Decision-making in Rheumatoid arthritis (RA) is often based on non-
speciﬁc disease outcome measures as improvement in Health-Related Quality of Life 
(HRQoL). It is therefore crucial that HRQoL discriminate across RA severity. Several 
utility measures have been validated, from either direct (i.e. standard gamble) or 
indirect methods (i.e. EuroQol [EQ-5D], Brazier’s Short Form-6D [SF-6D], VAS-
QoL). These utility values are commonly mapped to the Health Assessment Question-
naire (HAQ) to discriminate HRQoL across different RA disease states. We evaluated 
whether the EQ-5D, SF-6D and the VAS would lead to similar utility values and dis-
criminate across disease severity among a cohort of RA patients in Portugal. 
METHODS: Using a biannual cohort of Portuguese RA patients since 2003 (NDB-
Portugal), a total of 713 patients were included in this study. Utility measures were 
assigned to each level of HAQ using 0.50 intervals. Mean and standard deviation 
utility measures were calculated using the last observation per patient. RESULTS: 
Utilities decreased as HAQ scores worsened. The mean utility values of patients varied 
signiﬁcantly depending on the measurement method. Mean utility measured using the 
EuroQOL-5D was 0.48 and mean HAQ was 1.4 (0–3, 3 corresponding to the worst 
disability). Utilities per HAQ intervals using SF-6D did not differentiate across levels 
of disease severity (HAQ 0–0.5  0.67 ; HAQ 2.5–3  0.55). The EQ-5D differentiated 
more across the severity groups (HAQ 0–0.5  0.83 ; HAQ 2.5–3  0.08). VAS-Qol 
only discriminated marginally (HAQ 0–0.5  0.74 ; HAQ 2.5–3  0.45). CONCLU-
SIONS: In a cohort of Portuguese RA patients, different utility measurement in- 
struments resulted in different utility scores. Furthermore, not all utility measures 
discriminated across disease severity. Decision-making relying on these measures, the 
results of this analysis show that different utility measurement instruments may lead 
to signiﬁcantly different results. This may lead to potentially different resource alloca-
tion decisions.
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OBJECTIVES: The aim of this study was to determine the reliability and validity of 
the Social Functioning Scale (SFS) for the Turkish MSDs (Musculoskeletal disorders) 
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patients. METHODS: The scale, which was translated into English from Turkish, 
again translated back into English by two independent translators, was applied to 32 
MSDs patiets for pre-test. Non working questions applied to a target group were re-
tested and then the scale was applied to the bulk of subjects (N  82). Cronbach’s 
Alfa was used to assess reliability and factor analysis to assess dimensionality. The 
EuroQol-5D was used for concurrent validity. RESULTS: Among the patients were 
15.9% ankylosing spondylitis, 6.1% rheumatoid arthritis, 24.4% osteoarthritis, 
12.2% osteoporosis, 13.4% radiculitis, 9.8% ﬁbromyalgia, 2.4% stroke, 15.9% rheu-
matic disease. The internal consistency coefﬁcient (Cronbach’s alpha) of SFS was 0.68. 
Factor analysis of the scale revealed that it was composed of three factors with Eigen-
values  1, accounting for 90.8% of the total variance. All items of the Turkish SFS 
had a factor load ranging from 0.40 to 0.77 There was a strong relationship between 
Social Functioning Scale and EuroQoL 5D. CONCLUSIONS: The Social Functioning 
Scale has good validity and reliability for Turkish MSDs patient.
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OBJECTIVES: Psoriatic arthritis (PsA) and rheumatoid arthritis (RA) are inﬂamma-
tory arthritis with signiﬁcant impact on patients’ health related quality of life (HRQL). 
The main goal of this study is to analyse the HRQL measures in these conditions. 
METHODS: Two cross sectional questionnaire surveys of consecutive patients with 
PsA (2008) and with RA (2004) were conducted in the same rheumatology outpatient 
centres in Hungary. Patients ﬁlled in the generic EQ-5D and the disease speciﬁc Health 
Assessment Questionnaire (HAQ), Psoriatic Arthritis Quality of Life Questionnaire 
(PsAQoL) / Rheumatoid Arthritis Quality of Life Questionnaire (RAQoL). Assessing 
construct validity, patients were grouped by disease severity based on the yearly 
number of admissions to hospital, being on disability pension, use of devices and resort 
to help from others for everyday activities. The magnitude of difference between 
groups, the effect size was calculated as the standardized mean difference. Convergent 
validity was investigated by calculating the Spearman’s correlation between clinical 
scale variables and HRQL instruments. RESULTS: A total of 183 AP and 255 RA 
patients were enrolled. HRQL instruments’ scores were closer to the worse end of 
scales in case of severe PsA and RA, the highest effect size of each HRQL instrument 
was detected at use of home care. Strong correlations (rho  0.5) were observed 
between the EQ-5D, the PsAQoL / RAQoL, the HAQ disability score, the patient pain 
and global VAS. Disease duration of PsA and RA correlated weakly (rho  0.29) with 
all the HRQL instruments. CONCLUSIONS: Our results conﬁrm the good ability of 
EQ-5D, HAQ, PsAQoL/RAQoL to describe health state in PsA and RA. Our study is 
the ﬁrst to establish the correlation of HRQL instruments in PsA.
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Strand V1, Fleischmann R2, Kvien TK3, Kavanaugh A4, Smolen J5, Wells AF6, Nikai E7,  
Coteur G7, Combe B8
1Stanford University, Portola Valley, CA, USA, 2Univeristy of Texas Southwestern Medical 
Center, Dallas, TX, USA, 3Diakonhjemmet Hospital, Oslo, Norway, 4University of California, 
San Diego, LaJolla, CA, USA, 5Medical University of Vienna, Vienna, Austria, 6Rosalind 
Franklin University of Medicine and Science, Oak Creek, WA, USA, 7UCB, Brussels, Belgium, 
8Hopital Lapeyronie, Montpellier, France
OBJECTIVES: CZP 200 or 400 mg Q2W  methotrexate (MTX) signiﬁcantly 
improved HRQoL in patients with active RA over 1 year. Here we evaluated HRQoL 
in RA patients following long-term CZPMTX treatment. METHODS: Patients who 
completed 52 weeks treatment in RAPID 1 (completers) were eligible to enter an 
open-label (OL) study with CZP 400 mg Q2W  MTX. HRQoL was assessed using 
the SF-36 Survey that includes 8 domains (physical functioning [PF], role physical 
[RP], bodily pain [BP], general health [GH], vitality [VT], social functioning [SF], role 
emotional [RE] and mental health [MH]) grouped into summary scores: Physical (PCS) 
and Mental (MCS). MCIDs are 2.5 points for PCS/MCS and 5 for domain scores. 
Mean changes from baseline in HRQoL were analysed in completers at Week 100; 
domain scores were compared with US population norms (age/gender matched). 
RESULTS: CZP completers reported rapid and marked improvements in HRQoL at 
Weeks 12 (1st assessment) and 52 that were sustained to 100 weeks. Completers 
originally receiving CZP 200mg  MTX had mean PCS and MCS improvements of 
7.2 and 8.8 points, respectively, at Week 12, 9.1 and 8.2 points at Week 52, and 10.1 
and 7.7 points at Week 100; improvements were similar in patients originally receiving 
CZP 400 mg  MTX. Improvements in RE, GH and MH were sustained following 
long-term OL treatment, and met or exceeded MCID in PF, RP, BP and VT, which 
had the largest decrements at baseline. After 100 weeks of CZPMTX, BP, VT, SF 
and MH scores approached or met normative values. CONCLUSIONS: CZPMTX 
treatment results in rapid and clinically meaningful improvements in PCS, MCS and 
all SF-36 domains that were sustained over 2 years. BP, VT, SF and MH approached 
or met age/gender matched US population norms. Comparable beneﬁts were reported 
in RA patients enrolled in both CZP treatment arms.
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OBJECTIVES: Utility, one single value of quality of life ranged from 0 to 1, is known 
to differ between countries and available data in French population are sparse. This 
study reports on the effect of different fractures sites on self-reported EQ-5D in the 
post-menopausal osteoporosis population. METHODS: This cross-sectional study 
was carried out in general population by self completion questionnaire. Eligible 
women were those diagnosed for osteoporosis and aged 50 years and over. Utility was 
assessed using the index and VAS (range: 0–100) scores of the EQ-5D. For each group, 
the mean EQ-5D scores are reported. Univariate analysis on EQ5D index score permit-
ted to select covariables. As commonly used in health status studies, multivariate linear 
model including previous variables was performed in order to identify factors that 
most affected respondents’ EQ-5D scores. RESULTS: Questionnaires from a total of 
637 osteoporotic women were analysed. Among them, 228 already suffered a fracture. 
Last osteoporotic fracture sites reported were hip (N  22), vertebrae (N  45), wrist 
(N  80), rib (N  65), and others (N  16). Fractured women were older (mean age: 
70.3 o 8.1 vs 67.0 o 7.1 years; p  0.0001), had higher BMI values (p  0.0167) than 
others. When adjusted for age, the index and VAS scores of the EQ-5D were both 
signiﬁcantly different (p  0.01) between fractured (0.72 o 0.25; 68.3 o 16.46) and 
non fractured women (0.77 o 0.20; 72.3 o 14.82). Moreover, patient’s utility signiﬁ-
cantly decreased for hip and vertebral fractures with 0.114 and 0.102, respectively 
(p  0.01). However, loss of utility for patient with other fractures was not signiﬁcant 
(0.017; p  0.41). CONCLUSIONS: Both hip and vertebral fractures showed durable 
loss of utility, whereas other osteoporotic sites do not. Used for cost-utility analyses, 
mean QALYs of fractures for French osteoporotic population could be also 
calculated.
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IMPROVEMENTS IN THE PRODUCTIVITY OF PATIENTS WITH ACTIVE 
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OBJECTIVES: The impact of rheumatoid arthritis (RA) on patients’ work ability is 
well established. However, there is growing recognition of the impact on patients’ 
ability to perform household duties and social activities. This evaluates the impact of 
certolizumab pegol (CZP) plus methotrexate (MTX) on productivity within and 
outside the home in patients with active RA. METHODS: In RAPID1 and 2, produc-
tivity was assessed 4-weekly from baseline using the novel validated Work Productivity 
Survey (WPS-RA) that measures productivity limitations due to RA on work outside 
the home, household work and social activities. Mean changes from baseline in missed 
days of household work, days with reduced household productivity, missed days of 
family/social/leisure activities, self-reported work absenteeism and presenteeism (work 
days with productivity reduced by q50%) and RA impact on productivity a 0–10 scale 
(10  complete interference) were compared between treatment arms using non-para-
metric bootstrap-t methodology. RESULTS: A total 982 and 619 patients were ran-
domized into RAPID1, and 2, respectively. Baseline employment rates were 41.6% 
and 39.8%, respectively. The other patients included homemakers, retirees, those 
unable to work due to RA, and those unemployed for other reasons. Within each trial, 
treatment groups were comparable at baseline for productivity within and outside the 
home. In both trials, improvements in productivity within and outside the home were 
observed in the CZP arms as early as Week 4, and maintained until study end 
(RAPID1: 12 months, RAPID2: 6 months). In RAPID1, patients on CZP 200 mgMTX 
reported signiﬁcant decreases at Week 24 in days missed of household work (mean 
change 4.67 vs 1.54 days/month for MTX alone) and days with reduced productiv-
ity (mean change 5.68 vs 2.85 days/month for MTX alone). Similar improvements 
were reported with CZP 400 mgMTX and in RAPID2. Improvements in work pro-
ductivity and daily activities were reported. CONCLUSIONS: CZP improves produc-
tivity within and outside the home in RA patients.
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OBJECTIVES: To investigate the work related aspects of the burden of RA for 
patients. METHODS: A cross-sectional survey was conducted among working age 
RA patients (20 to 65 years old), members of one of the RA patients’ associations in 
France. The questionnaire was self-administered and used three validated instruments, 
the Health Assessment Questionnaire (HAQ), the EuroQoL-5 Dimension (EQ-5D) 
and the Working Productivity and Activity Impairment Questionnaire-RA (WPAI-
RA). RESULTS: A total of 3494 questionnaires were mailed and 1,189 (34.0%) could 
